Drug Profile


Alternative Names: Reminertant; SR 48692

Latest Information Update: 28 Feb 2006

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Analgesics; Antineoplastics; Antipsychotics
  • Mechanism of Action Neurotensin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anorexia nervosa; Cancer; Colorectal cancer; Irritable bowel syndrome; Pain; Pancreatic cancer; Prostate cancer; Schizophrenia; Small cell lung cancer

Most Recent Events

  • 24 Feb 2006 Discontinued - Phase-II for Small cell lung cancer in France (unspecified route)
  • 10 Mar 2005 Discontinued - Phase-II for Anorexia nervosa in France (unspecified route)
  • 10 Mar 2005 Discontinued - Phase-II for Pancreatic cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top